Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Original investigation

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

Authors: Julie R. Lundgren, Kristine Færch, Daniel R. Witte, Anna E. Jonsson, Oluf Pedersen, Torben Hansen, Torsten Lauritzen, Jens J. Holst, Dorte Vistisen, Marit E. Jørgensen, Signe S. Torekov, Nanna B. Johansen

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background and aim

Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and CVD.

Methods

This cross-sectional study included 837 Danish individuals from the ADDITION-PRO cohort (52% men, median (interquartile range) age 65.5 (59.8 to 70.7) years, BMI 26.1 (23.4 to 28.5) kg/m2, without antihypertensive treatment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and sex.

Results

A greater GLP-1 response was associated with lower central systolic and diastolic BP of − 1.17 mmHg (95% confidence interval (CI) − 2.07 to − 0.27 mmHg, P = 0.011) and − 0.74 mmHg (95% CI − 1.29 to − 0.18 mmHg, P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of − 1.27 mmHg (95% CI − 2.20 to − 0.33 mmHg, P = 0.008) and − 1.00 (95% CI − 1.56 to − 0.44 mmHg, P = 0.001), respectively. PWV was not associated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: − 4.94 (95% CI − 8.56 to − 1.31) mmHg, central diastolic BP: − 3.05 (95% CI − 5.29 to − 0.80) mmHg, brachial systolic BP: − 5.18 (95% CI − 8.94 to − 1.42) mmHg, and brachial diastolic BP: − 2.96 (95% CI − 5.26 to − 0.67) mmHg).

Conclusion

Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD and mortality.
Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005
Literature
1.
2.
3.
Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418.PubMedPubMedCentralCrossRef
4.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef
5.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef
6.
Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986.PubMedPubMedCentralCrossRef
7.
McIntosh CHS, Widenmaier S, Kim SJ. Pleiotropic actions of the incretin hormones. Vitamins and hormones. Waltham: Academic Press; 2010. p. 21–79.
8.
Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009–13.PubMedCrossRef
9.
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4):665–73.PubMedCrossRef
10.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–20.PubMedPubMedCentralCrossRef
11.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedCrossRef
12.
Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59–66.PubMedCrossRef
13.
Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003;144(6):2242–52.PubMedCrossRef
14.
Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157(8):1340–51.PubMedPubMedCentralCrossRef
15.
Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW, et al. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond). 2014;127(3):163–70.CrossRef
16.
Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737–49.PubMedCrossRef
17.
Johansen NB, Hansen ALS, Jensen TM, Philipsen A, Rasmussen SS, Jørgensen ME, et al. Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health. 2012;12:1078.PubMedPubMedCentralCrossRef
18.
Færch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes. 2015;64(7):2513–25.PubMedCrossRef
19.
Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159–66.PubMedCrossRef
20.
Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329(1):386–90.PubMedCrossRef
21.
Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481–9.PubMedPubMedCentralCrossRef
22.
Lee Y-S, Jun H-S. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat Inflamm. 2016;2016:3094642.
23.
Wang F, Song X, Zhou L, Liang G, Huang F, Jiang G, et al. The downregulation of sweet taste receptor signaling in enteroendocrine L-cells mediates 3-deoxyglucosone-induced attenuation of high glucose-stimulated GLP-1 secretion. Arch Physiol Biochem. 2018;124(5):430–5.PubMedCrossRef
24.
Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57(5):1340–8.PubMedCrossRef
25.
26.
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.PubMedPubMedCentralCrossRef
27.
Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension. Endocrinol Metab Clin North Am. 2014;43(1):103–22.PubMedCrossRef
28.
Iepsen EW, Lundgren J, Dirksen C, Jensen J-EB, Pedersen O, Hansen T, Madsbad S, Holst JJ, Torekov SS. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes. 2015;39(5):834–41.CrossRef
29.
Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(7):639–43.PubMedCrossRef
30.
Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(5):451–6.PubMedCrossRef
31.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.PubMedCrossRef
32.
Heerspink HJL, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (London, England). 2009;373(9668):1009–15.PubMedCentralCrossRef
33.
Yuasa S, Sato K, Furuki T, Minamizawa K, Sakai H, Numata Y, et al. Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes. J Clin Med Res. 2017;9(3):188–92.PubMedPubMedCentralCrossRef
34.
Foley JE, Evans M, Schweizer A. Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in > 2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vasc Health Risk Manag. 2016;12:337–40.PubMedPubMedCentralCrossRef
35.
Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–8.PubMedCrossRef
36.
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524–36.PubMedCrossRef
37.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.PubMedCrossRef
38.
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.PubMedCrossRef
39.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.PubMedCrossRef
40.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.PubMedCrossRef
41.
Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Metab. 2004;287(6):E1209–15.
42.
Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125(1–3):173–7.PubMedCrossRef
43.
44.
Goud A, Zhong J, Peters M, Brook RD, Rajagopalan S. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18(2):16.PubMedCrossRef
45.
Vincent MA, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes. 2004;53(6):1418–23.PubMedCrossRef
46.
Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, et al. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8.PubMedPubMedCentralCrossRef
47.
Ecobici M, Stoicescu C. Arterial stiffness and hypertension—which comes first? Maedica (Buchar). 2017;12(3):184–90.
48.
Ishikawa S, Shimano M, Watarai M, Koyasu M, Uchikawa T, Ishii H, et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol. 2014;114(3):384–8.PubMedCrossRef
49.
Kishimoto S, Kinoshita Y, Matsumoto T, Maruhashi T, Kajikawa M, Matsui S, et al. Effects of the dipeptidyl peptidase 4 inhibitor alogliptin on blood pressure in hypertensive patients with type 2 diabetes mellitus. Am J Hypertens. 2019;32(7):695–702.PubMedCrossRef
50.
Ramírez E, Picatoste B, González-Bris A, Oteo M, Cruz F, Caro-Vadillo A, et al. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking. Cardiovasc Diabetol. 2018;17(1):12.PubMedPubMedCentralCrossRef
51.
Zhang X, Zhang Z, Yang Y, Suo Y, Liu R, Qiu J, et al. Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits. Cardiovasc Diabetol. 2018;17(1):160.PubMedPubMedCentralCrossRef
52.
Ferreira JP, Girerd N, Bozec E, Machu JL, Boivin J-M, London GM, et al. Intima-media thickness is linearly and continuously associated with systolic blood pressure in a population-based cohort (STANISLAS cohort study). J Am Heart Assoc. 2016;5(6):e003529.PubMedPubMedCentralCrossRef
53.
Lalande S, Johnson DB. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today. 2008;44(7):503.CrossRef
54.
Kushima H, Mori Y, Koshibu M, Hiromura M, Kohashi K, Terasaki M, et al. The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovasc Diabetol. 2017;16(1):122.PubMedPubMedCentralCrossRef
55.
56.
Chen Y, Zhang X, He J, Xie Y, Yang Y. Delayed administration of the glucagon-like peptide 1 analog liraglutide promoting angiogenesis after focal cerebral ischemia in mice. J Stroke Cerebrovasc Dis. 2018;27(5):1318–25.PubMedCrossRef
57.
Yoshihara M, Akasaka H, Ohnishi H, Miki T, Furukawa T, Yuda S, et al. Glucagon-like peptide-1 secretory function as an independent determinant of blood pressure: analysis in the Tanno-Sobetsu study. PLoS ONE. 2013;8(7):e67578.PubMedPubMedCentralCrossRef
58.
Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, et al. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol. 2013;12(1):117.PubMedPubMedCentralCrossRef
59.
Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsbøll T, Jørgensen NB, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab. 2014;16(11):1155–64.PubMedCrossRef
60.
Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535–9.PubMedCrossRef
61.
Clarke SJ, Pettit S, Giblett JP, Zhao T, Kydd AC, Albrechtsen NJW, et al. Effects of acute GLP-1 infusion on pulmonary and systemic hemodynamics in patients with heart failure: a pilot study. Clin Ther. 2019;41(1):118–27.PubMedCrossRef
62.
Smits MM, Tonneijck L, Muskiet MHA, Hoekstra T, Kramer MHH, Diamant M, et al. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. Eur J Endocrinol. 2017;176(1):77–86.PubMedCrossRef
63.
Monnard CR, Fellay B, Scerri I, Grasser EK. Substantial inter-subject variability in blood pressure responses to glucose in a healthy, non-obese population. Front Physiol. 2017;8:507.PubMedPubMedCentralCrossRef
64.
Grasser EK, Dulloo A, Montani J-P. Cardiovascular responses to the ingestion of sugary drinks using a randomised cross-over study design: does glucose attenuate the blood pressure-elevating effect of fructose? Br J Nutr. 2014;112(2):183–92.PubMedCrossRef
65.
Brown CM, Dulloo AG, Yepuri G, Montani J-P. Fructose ingestion acutely elevates blood pressure in healthy young humans. Am J Physiol Integr Comp Physiol. 2008;294(3):R730–7.CrossRef
Metadata
Title
Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures
Authors
Julie R. Lundgren
Kristine Færch
Daniel R. Witte
Anna E. Jonsson
Oluf Pedersen
Torben Hansen
Torsten Lauritzen
Jens J. Holst
Dorte Vistisen
Marit E. Jørgensen
Signe S. Torekov
Nanna B. Johansen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0937-7

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue

Original investigation

Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis

Review

Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease

Original investigation

The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension

Original investigation

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction

Original investigation

The association of diabetes mellitus treated with oral antidiabetic drugs and insulin with mortality after transcatheter valve implantation: a 3-year follow-up of the TAVIK registry

Original investigation

Association of haptoglobin phenotype with incident acute myocardial infarction in Chinese patients with type 2 diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits